Access to CAR-T cell therapy in Central and Eastern Europe: persistent barriers and inequalities as of October/November 2025
Eastern European countries face major barriers accessing approved cancer cell therapies, highlighting urgent need for equitable reimbursement and infrastructure.
A letter correspondence from multiple CEE centers documents ongoing barriers to CAR-T cell therapy access including reimbursement gaps, infrastructure limitations, and geographic inequalities across Eastern European countries. These access inequities represent a major public health challenge in the implementation of approved cell therapies.
What the study was
- Study design
- Survey/correspondence
- Population
- CAR-T therapy centers in Central and Eastern Europe
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- Bone Marrow Transplantation
Why it surfaced
Letter correspondence — excluded by default publication type rules. Flagged for completeness. Access inequities in CAR-T are a relevant policy topic but the letter design precludes pipeline inclusion.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.